Meeting
2024 ASCO Annual Meeting
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
Authors
Martin W. Schoen
Saint Louis University School of Medicine, St. Louis, MO
Martin W. Schoen , Ruth Douglas Etzioni , Suhong Luo , Danielle Candelieri , Nicholas Fedele , Priya Baxi , Carley Pickett , Forest Riekhof , Kara Ingram , Krishny Karunanandaa , Srinivas Govindan , Nina Cheranda , Eric Marshall Knoche , Robert Bruce Montgomery
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5092)
DOI
10.1200/JCO.2024.42.16_suppl.5092
Abstract #
5092
Poster Bd #
498
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.
First Author: Marc-Oliver Grimm
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
First Author: Alyssa Liang
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment and survival of de novo metastatic prostate cancer in US veterans.
First Author: Martin W. Schoen
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
First Author: Shunsuke Kamijo